Paid Clinical Trials Bismarck
Discover 55 paid clinical trials in Bismarck, North Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Neoadjuvant Chemotherapy vs. ChemoradiotherapyNeoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Sponsor:
Canadian Cancer Trials Group
Location:
Code:
NCT06205485
Conditions
Rectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Leucovorin
Oxaliplatin
Fluoruracil
Capecitabine
Radiation
Nipent, Cytoxan, RituxanEfficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Sponsor:
East Valley Hematology and Oncology Medical Group
Location:
Code:
NCT00131313
Conditions
Chronic Lymphocytic Leukemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Nipent, Cytoxan, Rituxan
Sacituzumab Tirumotecan & PembrolizumabSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06393374
Conditions
Triple-Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
Sacituzumab tirumotecan
Capecitabine
Chemotherapy & ImmunotherapyChemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05001880
Conditions
Peritoneal Malignant Mesothelioma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Bevacizumab
Biospecimen Collection
Carboplatin
Computed Tomography
Focused Radiation & Systemic TherapyFocused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT05863351
Conditions
Metastatic Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Computed Tomography
Magnetic Resonance Imaging
Questionnaire Administration
Stereotactic Ablative Radiotherapy
Systemic Therapy
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Targeted TherapyTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05564377
Conditions
Advanced Malignant Solid Neoplasm
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Malignant Solid Neoplasm
Malignant Female Reproductive System Neoplasm
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Alpelisib
Binimetinib
Biopsy Procedure
Biospecimen Collection
Bone Marrow Aspiration
Ado-Trastuzumab Emtansine vs. ChemotherapyTesting the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Sponsor:
NRG Oncology
Location:
Code:
NCT05408845
Conditions
Metastatic Salivary Gland Carcinoma
Recurrent Salivary Gland Carcinoma
Stage III Major Salivary Gland Cancer AJCC v8
Stage IV Major Salivary Gland Cancer AJCC v8
Unresectable Salivary Gland Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy Procedure
Biospecimen Collection
Computed Tomography
Docetaxel
Echocardiography Test
Nivolumab & IpilimumabA Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT02339571
Conditions
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Echocardiography Test
Ipilimumab
Magnetic Resonance Elastography
BiomarkersUsing Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT04462406
Conditions
Advanced Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ipilimumab
Nivolumab
Patient Observation
Pembrolizumab
Durvalumab & TremelimumabA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Sponsor:
AstraZeneca
Location:
Code:
NCT06008093
Conditions
Carcinoma, Non-Small-Cell Lung
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Durvalumab
Tremelimumab
Pemetrexed
Pembrolizumab
Carboplatin